Devin Oglesbee, Ph.D., Director of the Biochemical and Molecular Genetics Laboratories at Mayo Clinic, provides an overview of the lysosomal storage disease panel, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.
To ensure we continue to provide the highest level of value-based reference laboratory services, Mayo Medical Laboratories will be implementing a new pathology laboratory information system on Friday, Sept. 8, 2017. View the list of orderable pathology tests included in the system upgrade.
An algorithm is a step-by-step procedure to guide clinicians and laboratorians in appropriate laboratory test ordering.
The algorithm can be viewed here.
In May 2017, Mayo Medical Laboratories announced eight brand new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Useful For Video Overview Clinical Information Several PSA isoforms have been identified that can further increase the specificity of PSA for prostate cancer.[...]
European Heart Journal recently highlighted Mayo Clinic's new blood test that may predict cardiovascular events in patients with or without coronary artery disease.
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.
A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.